Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®) for severe pain, which can be adequately managed only with opioid analgesics.
|05/05/2010||12/07/2010||Reimbursement not recommended|
|19/10/2010||Reimbursement recommended following price revision|
We do not recommend reimbursement of oxycodone/naloxone (Targin®) under the Community Drugs Schemes at the proposed price.
Following a price revision oxycodone/naloxone (Targin®) is now reimbursed under the Community Drugs Schemes.